Viktor Levitski

This inventor holds 13 USPTO granted patents and 15 published patent applications, plus 3 CIPO patents and 8 EPO patents, primarily in Cancer Immunotherapy. Top assignees: Hoffmann-La Roche Inc., F. Hoffmann-La Roche Ag. Active years: 2019-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Viktor Levitski. Retrieved from https://idiyas.com/inventor/viktor-levitski

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 13 (Patent Applications = 15)

% Patents Active = 100.0

CIPO Patents = 3 (Patent Applications = 4)

EPO Patents = 8 (Patent Applications = 14)

Average Co-Inventor Count = 9.8

ph-index = 6

Forward Citations = 120(Granted Patents)

Company Filing History:

12 out of 5,028

Hoffmann-La Roche Inc.

patents

1 out of 181

F. Hoffmann-La Roche Ag

patents

Years Active: 2019-2026

Loading Chart...

Areas of Expertise:

Cancer Treatment

Bispecific Antibodies

TNF Family Ligand

Antigen-Binding Molecules

Tumor Necrosis Factor

PD1

TIM3

OX40

Combination Therapy

Targeted Therapy

13 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12565530 - COMBINATION THERAPY WITH TARGETED 4-1BB (CD137) AGONISTS/ANTI-FAP BINDING DOMAIN AND ANTI-CEA/ANTI-CD3 BISPECIFIC ANTIBODY (2026-03-03),

2. 12441812 - Methods of treating cancer by administering tumor necrosis factor (TNF) family ligand trimer-containing antigen-binding molecules (2025-10-14),

3. 12391757 - Bispecific antibodies specific for PD1 and TIM3 (2025-08-19),

4. 12240911 - Bispecific antibodies specific for OX40 (2025-03-04),

5. 12202870 - Antigen binding molecules comprising a trimeric TNF family ligand and encoding polynucleotides thereof (2025-01-21),

6. 11306154 - Methods of treating cancer by administering antigen-binding molecules comprising a TNF family ligand trimer (2022-04-19),

7. 11267903 - Antigen-binding molecules comprising a tumor necrosis factor (TNF) family ligand trimer (2022-03-08),

8. 11149083 - Antigen binding molecules comprising a TNF family ligand trimer and a Tenascin binding moiety (2021-10-19),

9. 11130810 - Bispecific antibodies specific for PD1 and TIM3 (2021-09-28),

10. 10526413 - Bispecific antibodies specific for OX40 (2020-01-07),

11. 10464981 - Tumor necrosis factor (TNF) family ligand trimer-containing antigen binding molecules (2019-11-05),

12. 10392445 - Tumor necrosis factor (TNF) family ligand trimer-containing antigen-binding molecules (2019-08-27),

13. 10287352 - Bispecific antibodies specific for PD1 and TIM3 (2019-05-14),

Title: Inventor Viktor Levitski

Introduction: Viktor Levitski is a renowned inventor based in Schlieren, Switzerland, known for his groundbreaking contributions to various technological fields.

Latest Patents: Viktor Levitski holds several patents in the areas of renewable energy, nanotechnology, and medical devices, showcasing his diverse range of expertise and innovation.

Career Highlights: With a career spanning over two decades, Viktor Levitski has worked with leading research institutions and companies to develop cutting-edge solutions that have had a significant impact on the industry.

Collaborations: Throughout his career, Viktor Levitski has collaborated with top scientists, engineers, and inventors globally, fostering a culture of innovation and knowledge exchange.

Conclusion: Viktor Levitski's passion for innovation and his relentless pursuit of excellence continue to inspire the next generation of inventors and shape the future of technology.

Profile summary based on public USPTO records.